Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Among authors: wheler jj. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. Janku F, et al. Among authors: wheler jj. Oncotarget. 2012 Dec;3(12):1566-75. doi: 10.18632/oncotarget.716. Oncotarget. 2012. PMID: 23248156 Free PMC article.
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Subbiah IM, et al. Among authors: wheler jj. Oncotarget. 2013 Jan;4(1):156-65. doi: 10.18632/oncotarget.832. Oncotarget. 2013. PMID: 23391555 Free PMC article. Clinical Trial.
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Wheler JJ, et al. Mol Cancer Ther. 2013 Oct;12(10):2167-75. doi: 10.1158/1535-7163.MCT-12-1208. Epub 2013 Aug 20. Mol Cancer Ther. 2013. PMID: 23963360 Free PMC article. Clinical Trial.
148 results